Assenagon Asset Management S.A. Sells 434,830 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Assenagon Asset Management S.A. lessened its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 60.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 286,644 shares of the company's stock after selling 434,830 shares during the period. Assenagon Asset Management S.A. owned about 0.47% of Dyne Therapeutics worth $3,812,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its holdings in shares of Dyne Therapeutics by 49.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,510 shares of the company's stock worth $39,000 after purchasing an additional 1,155 shares during the last quarter. Royal Bank of Canada boosted its holdings in Dyne Therapeutics by 72.8% in the second quarter. Royal Bank of Canada now owns 5,078 shares of the company's stock valued at $57,000 after acquiring an additional 2,140 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $83,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Dyne Therapeutics by 58.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company's stock valued at $75,000 after acquiring an additional 3,092 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Dyne Therapeutics by 560.1% in the second quarter. Tower Research Capital LLC TRC now owns 8,403 shares of the company's stock valued at $95,000 after acquiring an additional 7,130 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Raymond James upped their target price on Dyne Therapeutics from $27.00 to $56.00 and gave the company a "strong-buy" rating in a report on Thursday, January 4th. Stifel Nicolaus upped their target price on Dyne Therapeutics from $35.00 to $41.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. Chardan Capital boosted their price target on Dyne Therapeutics from $20.00 to $31.00 and gave the company a "buy" rating in a research note on Friday, March 8th. StockNews.com raised Dyne Therapeutics to a "sell" rating in a research note on Thursday, December 21st. Finally, Piper Sandler boosted their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.43.

Dyne Therapeutics Stock Down 0.6 %

NASDAQ DYN traded down $0.16 on Tuesday, reaching $27.84. The company had a trading volume of 977,995 shares, compared to its average volume of 2,257,930. The stock has a market capitalization of $2.28 billion, a P/E ratio of -7.11 and a beta of 0.95. The company's fifty day moving average is $24.50 and its 200 day moving average is $15.69. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $30.27.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.17). On average, research analysts expect that Dyne Therapeutics, Inc. will post -3.23 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CEO Joshua T. Brumm sold 218,536 shares of the company's stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $18.51, for a total value of $4,045,101.36. Following the completion of the transaction, the chief executive officer now owns 584,971 shares in the company, valued at approximately $10,827,813.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Wildon Farwell sold 1,585 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the transaction, the insider now owns 151,590 shares in the company, valued at approximately $3,895,863. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joshua T. Brumm sold 218,536 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $18.51, for a total value of $4,045,101.36. Following the transaction, the chief executive officer now owns 584,971 shares of the company's stock, valued at approximately $10,827,813.21. The disclosure for this sale can be found here. Insiders sold 2,165,394 shares of company stock worth $49,837,369 in the last quarter. 32.89% of the stock is currently owned by company insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.